
Citrome discussed the limitations of indirect comparisons and the need for head-to-head trials evaluating adjunctive atypical antipsychotics for MDD, including lumateperone.

Citrome discussed the limitations of indirect comparisons and the need for head-to-head trials evaluating adjunctive atypical antipsychotics for MDD, including lumateperone.

A study suggested lumateperone demonstrated favorable efficacy outcomes and limited weight gain and akathisia risk compared with other adjunctive antipsychotics for MDD.